Validation of IMP dehydrogenase inhibitors in a mouse model of cryptosporidiosis

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 3, 2014, Pages 1603-1614

  Gorla, Suresh Kumar ^a   McNair, Nina N ^b   Yang, Guangyi ^c   Gao, Song ^c   Hu, Ming ^b   Jala, Venkatakrishna R ^d   Haribabu, Bodduluri ^d   Striepen, Boris ^e   Cuny, Gregory D ^c,f   Mead, Jan R ^b   Hedstrom, Lizbeth ^a  

^a BRANDEIS UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF HOUSTON   (United States)

^d University of Louisville School of Medicine   (United States)

^e UNIVERSITY OF GEORGIA   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 110; A 119; ANGIOTENSIN II AMIDE 8 ALANINE; ANTIPROTOZOAL AGENT; GENOMIC DNA; INOSINATE DEHYDROGENASE; INOSINATE DEHYDROGENASE INHIBITOR; INTERLEUKIN 12; NITAZOXANIDE; P 131; P 82; P 83; PAROMOMYCIN; PHOSPHORUS 32; PRALIDOXIME MESILATE; RNA 16S; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIPROTOZOAL ACTIVITY; APICOMPLEXAN LIFE CYCLE STAGE; AREA UNDER THE CURVE; ARTICLE; BACTEROIDETES; CELL CULTURE; CELL STRAIN CACO 2; CONTROLLED STUDY; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM PARVUM; CYANOBACTERIUM; DISTRESS SYNDROME; DNA ISOLATION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PENETRATION; DRUG SCREENING; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG UPTAKE; ENTEROHEPATIC CIRCULATION; ENZYME INHIBITION; FECES MICROFLORA; FIRMICUTES; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE LIBRARY; GENE SEQUENCE; HUMAN; HUMAN CELL; HYDROPHOBICITY; IC 50; IN VITRO STUDY; IN VIVO STUDY; INTESTINE EPITHELIUM CELL; INTESTINE FLORA; KNOCKOUT MOUSE; LIQUID CHROMATOGRAPHY; LIVER METABOLISM; LIVER MICROSOME; MAXIMUM PLASMA CONCENTRATION; MDCK CELL; MICROBIAL COMMUNITY; MICROBIAL GROWTH; MOLLICUTES; MOUSE; MOUSE MODEL; MULTIPLE DRUG DOSE; NONHUMAN; OOCYST; PARASITE ISOLATION; PARASITE LOAD; PARASITEMIA; PHYLOGENETIC TREE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEOBACTERIA; PYROSEQUENCING; SEQUENCE ANALYSIS; SINGLE DRUG DOSE; SPOROZOITE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXOPLASMA GONDII; VALIDATION STUDY; VERRUCOMICROBIA; WEIGHT REDUCTION;

ANIMALS; CACO-2 CELLS; COCCIDIOSTATS; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM PARVUM; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; HUMANS; IMP DEHYDROGENASE; INTERLEUKIN-12; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT;

EID: 84896873219     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02075-13     Document Type: Article

References (87)

1. Chalmers RM, Davies AP. 2010. Minireview: clinical cryptosporidiosis. Exp. Parasitol. 124:138-146. http://dx.doi.org/10.1016/j.exppara.2009.02.003.
2. Desai NT, Sarkar R, Kang G. 2012. Cryptosporidiosis: an under-recognized public health problem. Trop. Parasitol. 2:91-98. http://dx.doi.org/10.4103/2229- 5070.105173.
3. Shirley DA, Moonah SN, Kotloff KL. 2012. Burden of disease from cryptosporidiosis. Curr. Opin. Infect. Dis. 25:555-563. http://dx.doi.org/10. 1097/QCO.0b013e328357e569.
4. Striepen B. 2013. Parasitic infections: time to tackle cryptosporidiosis. Nature 503:189-191. http://dx.doi.org/10.1038/503189a.
5. Hlavsa MC, Roberts VA, Anderson AR, Hill VR, Kahler AM, Orr M, Garrison LE, Hicks LA, Newton A, Hilborn ED, Wade TJ, Beach MJ, Yoder JS. 2011. Surveillance for waterborne disease outbreaks and other health events associated with recreational water - United States, 2007-2008. MMWR Surveill. Summ. 60:1-32.
6. Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH, Panchalingam S, Wu Y, Sow SO, Sur D, Breiman RF, Faruque AS, Zaidi AK, Saha D, Alonso PL, Tamboura B, Sanogo D, Onwuchekwa U, Manna B, Ramamurthy T, Kanungo S, Ochieng JB, Omore R, Oundo JO, Hossain A, Das SK, Ahmed S, Qureshi S, Quadri F, Adegbola RA, Antonio M, Hossain MJ, Akinsola A, Mandomando I, Nhampossa T, Acacio S, Biswas K, O'Reilly CE, Mintz ED, Berkeley LY, Muhsen K, Sommerfelt H, Robins-Browne RM, Levine MM. 2013. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet 382:209-222. http://dx.doi.org/10.1016/S0140-6736(13)60844-2.
7. Bartelt LA, Lima AA, Kosek M, Penataro Yori P, Lee G, Guerrant RL. 2013. "Barriers" to child development and human potential: the case for including the "neglected enteric protozoa" (NEP) and other enteropathy-associated pathogens in the NTDs. PLoS Negl. Trop. Dis. 7:e2125. http://dx.doi.org/10.1371/journal.pntd.0002125.
8. Hagen RM, Loderstaedt U, Frickmann H. 3 December 2013. An evaluation of the potential use of Cryptosporidium species as agents for deliberate release. J. R. Army Med. Corps http://dx.doi.org/10.1136/jramc-2013-000186.
9. MacKenzie WR, Hoxie NJ, Proctor ME, Gradus MS, Blair KA, Peterson DE, Kazmierczak JJ, Addiss DG, Fox KR, Rose JB, Davis JP. 1994. A massive outbreak in Milwaukee of cryptosporidium infection transmitted through the public water supply. N. Engl. J. Med. 331:161-167. http://dx.doi.org/10.1056/ NEJM199407213310304. (Pubitemid 24209566)
10. Rossignol JF, Kabil SM, el-Gohary Y, Younis AM. 2006. Effect of nitazoxanide in diarrhea and enteritis caused by Cryptosporidium species. Clin. Gastroenterol. Hepatol. 4:320-324. http://dx.doi.org/10.1016/j.cgh.2005.12.020. (Pubitemid 43343888)
11. Amadi B, Mwiya M, Musuku J, Watuka A, Sianongo S, Ayoub A, Kelly P. 2002. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Lancet 360:1375-1380. http://dx.doi.org/10.1016/S0140-6736(02)11401-2. (Pubitemid 35341302)
12. Hemphill A, Mueller J, Esposito M. 2006. Nitazoxanide, a broadspectrum thiazolide anti-infective agent for the treatment of gastrointestinal infections. Expert Opin. Pharmacother. 7:953-964. http://dx.doi.org/10.1517/ 14656566.7.7.953.
13. Cabada MM, White AC, Jr. 2010. Treatment of cryptosporidiosis: do we know what we think we know? Curr. Opin. Infect. Dis. 23:494-499. http://dx.doi.org/10.1097/QCO.0b013e32833de052.
14. Rehg JE. 1995. The activity of halofuginone in immunosuppressed rats infected with Cryptosporidium parvum. J. Antimicrob. Chemother. 35:391-397. http://dx.doi.org/10.1093/jac/35.3.391.
15. Downey AS, Chong CR, Graczyk TK, Sullivan DJ. 2008. Efficacy of pyrvinium pamoate against Cryptosporidium parvum infection in vitro and in a neonatal mouse model. Antimicrob. Agents Chemother. 52:3106-3112. http://dx.doi.org/10. 1128/AAC.00207-08.
16. Kimata I, Uni S, Iseki M. 1991. Chemotherapeutic effect of azithromycin and lasalocid on Cryptosporidium infection in mice. J. Protozool. 38:232S-233S.
17. Chen F, Huang K. 2012. Effects of the Chinese medicine matrine on experimental C. parvum infection in BALB/c mice and MDBK cells. Parasitol. Res. 111:1827-1832. http://dx.doi.org/10.1007/s00436-012-3030-7.
18. Rehg JE, Hancock ML. 1990. Effectiveness of arprinocid in the reduction of cryptosporidial activity in immunosuppressed rats. Am. J. Vet. Res. 51:1668-1670. (Pubitemid 20352369)
19. Moreno B, Bailey BN, Luo S, Martin MB, Kuhlenschmidt M, Moreno SN, Docampo R, Oldfield E. 2001. (31)P NMR of apicomplexans and the effects of risedronate on Cryptosporidium parvum growth. Biochem. Biophys. Res. Commun. 284:632-637. http://dx.doi.org/10.1006/bbrc.2001.5009. (Pubitemid 32924775)
20. Blagburn BL, Drain KL, Land TM, Kinard RG, Moore PH, Lindsay DS, Patrick DA, Boykin DW, Tidwell RR. 1998. Comparative efficacy evaluation of dicationic carbazole compounds, nitazoxanide, and paromomycin against Cryptosporidium parvum infections in a neonatal mouse model. Antimicrob. Agents Chemother. 42:2877-2882. (Pubitemid 28501219)
21. Fayer R, Fetterer R. 1995. Activity of benzimidazoles against cryptosporidiosis in neonatal BALB/c mice. J. Parasitol. 81:794-795. http://dx.doi.org/10.2307/3283980.
22. Stachulski AV, Berry NG, Lilian Low AC, Moores SL, Row E, Warhurst DC, Adagu IS, Rossignol JF. 2006. Identification of isoflavone derivatives as effective anticryptosporidial agents in vitro and in vivo. J. Med. Chem. 49:1450-1454. http://dx.doi.org/10.1021/jm050973f. (Pubitemid 43271898)
23. Kayser O, Waters WR, Woods KM, Upton SJ, Keithly JS, Laatsch H, Kiderlen AF. 2002. Evaluation of in vitro and in vivo activity of benzindazole-4,9- quinones against Cryptosporidium parvum. J. Antimicrob. Chemother. 50:975-980. http://dx.doi.org/10.1093/jac/dkf199. (Pubitemid 36032820)
24. Rueda C, Fenoy S, Simon F, Del Aguila C. 2008. Bobel-24 activity against Cryptosporidium parvum in cell culture and in a SCID mouse model. Antimicrob. Agents Chemother. 52:1150-1152. http://dx.doi.org/10.1128/AAC.01019-07. (Pubitemid 351358403)
25. Sun XE, Sharling L, Muthalagi M, Mudeppa DG, Pankiewicz KW, Felczak K, Rathod PK, Mead J, Striepen B, Hedstrom L. 2010. Prodrug activation by Cryptosporidium thymidine kinase. J. Biol. Chem. 285: 15916-15922. http://dx.doi.org/10.1074/jbc.M110.101543.
26. Castellanos-Gonzalez A, White AC, Jr, Ojo KK, Vidadala RS, Zhang Z, Reid MC, Fox AM, Keyloun KR, Rivas K, Irani A, Dann SM, Fan E, Dustin J, Van Voorhis WC. 2013. A novel calcium-dependent protein kinase inhibitor as a lead compound for treating cryptosporidiosis. J. Infect. Dis. 208:1342-1348. http://dx.doi.org/10.1093/infdis/jit327.
27. Abrahamsen MS, Templeton TJ, Enomoto S, Abrahante JE, Zhu G, Lancto CA, Deng M, Liu C, Widmer G, Tzipori S, Buck GA, Xu P, Bankier AT, Dear PH, Konfortov BA, Spriggs HF, Iyer L, Anantharaman V, Aravind L, Kapur V. 2004. Complete genome sequence of the apicomplexan, Cryptosporidium parvum. Science 304:441-445. http://dx.doi.org/10.1126/science.1094786. (Pubitemid 38495940)
28. Xu P, Widmer G, Wang Y, Ozaki LS, Alves JM, Serrano MG, Puiu D, Manque P, Akiyoshi D, Mackey AJ, Pearson WR, Dear PH, Bankier AT, Peterson DL, Abrahamsen MS, Kapur V, Tzipori S, Buck GA. 2004. The genome of Cryptosporidium hominis. Nature 431:1107-1112. http://dx.doi.org/10.1038/nature02977. (Pubitemid 39472235)
29. Striepen B, Pruijssers AJ, Huang J, Li C, Gubbels MJ, Umejiego NN, Hedstrom L, Kissinger JC. 2004. Gene transfer in the evolution of parasite nucleotide biosynthesis. Proc. Natl. Acad. Sci. U. S. A. 101:3154-3159. http://dx.doi.org/10.1073/pnas.0304686101. (Pubitemid 38327750)
30. Umejiego NN, Li C, Riera T, Hedstrom L, Striepen B. 2004. Cryptosporidium parvum IMP dehydrogenase: identification of functional, structural, and dynamic properties that can be exploited for drug design. J. Biol. Chem. 279:40320-40327. http://dx.doi.org/10.1074/jbc.M407121200. (Pubitemid 39287617)
31. Nelson RG, Rosowsky A. 2001. Dicyclic and tricyclic diaminopyrimidine derivatives as potent inhibitors of Cryptosporidium parvum dihydrofolate reductase: structure-activity and structure-selectivity correlations. Antimicrob. Agents Chemother. 45:3293-3303. http://dx.doi.org/10.1128/AAC.45.12. 3293-3303.2001. (Pubitemid 33107838)
32. Murphy RC, Ojo KK, Larson ET, Castellanos-Gonzalez A, Perera BG, Keyloun KR, Kim JE, Bhandari JG, Muller NR, Verlinde CL, White AC, Jr, Merritt EA, Van Voorhis WC, Maly DJ. 2010. Discovery of potent and selective inhibitors of calcium-dependent protein kinase 1 (CDPK1) from C. parvum and T. gondii. ACS Med. Chem. Lett. 1:331-335. http://dx.doi.org/10.1021/ml100096t.
33. Artz JD, Dunford JE, Arrowood MJ, Dong A, Chruszcz M, Kavanagh KL, Minor W, Russell RG, Ebetino FH, Oppermann U, Hui R. 2008. Targeting a uniquely nonspecific prenyl synthase with bisphosphonates to combat cryptosporidiosis. Chem. Biol. 15:1296-1306. http://dx.doi.org/10.1016/j.chembiol.2008.10.017. (Pubitemid 352841472)
34. Zhu G, Shi X, Cai X. 2010. The reductase domain in a type I fatty acid synthase from the apicomplexan Cryptosporidium parvum: restricted substrate preference towards very long chain fatty acyl thioesters. BMC Biochem. 11:46. http://dx.doi.org/10.1186/1471-2091-11-46.
35. Fritzler JM, Zhu G. 2012. Novel anti-Cryptosporidium activity of known drugs identified by high-throughput screening against parasite fatty acyl-CoA binding protein (ACBP). J. Antimicrob. Chemother. 67:609-617. http://dx.doi.org/10.1093/jac/dkr516.
36. Lei C, Rider SD, Jr, Wang C, Zhang H, Tan X, Zhu G. 2010. The apicomplexan Cryptosporidium parvum possesses a single mitochondrial-type ferredoxin and ferredoxin:NADP- reductase system. Protein Sci. 19:2073-2084. http://dx.doi.org/10.1002/pro.487.
37. Yarlett N, Waters WR, Harp JA, Wannemuehler MJ, Morada M, Bellcastro J, Upton SJ, Marton LJ, Frydman BJ. 2007. Activities of DL-alpha- difluoromethylarginine and polyamine analogues against Cryptosporidium parvum infection in a T-cell receptor alpha-deficient mouse model. Antimicrob. Agents Chemother. 51:1234-1239. http://dx.doi.org/10.1128/AAC.01040-06. (Pubitemid 46586799)
38. Fayer R. 2004. Cryptosporidium: a water-borne zoonotic parasite. Vet. Parasitol. 126:37-56. http://dx.doi.org/10.1016/j.vetpar.2004.09.004. (Pubitemid 39572936)
39. Huang DB, White AC. 2006. An updated review on Cryptosporidium and Giardia. Gastroenterol. Clin. North Am. 35:291-314. http://dx.doi.org/10.1016/j. gtc.2006.03.006. (Pubitemid 44118668)
40. Snelling WJ, Xiao L, Ortega-Pierres G, Lowery CJ, Moore JE, Rao JR, Smyth S, Millar BC, Rooney PJ, Matsuda M, Kenny F, Xu J, Dooley JS. 2007. Cryptosporidiosis in developing countries. J. Infect. Dev. Ctries. 1:242-256. http://dx.doi.org/10.3855/jidc.360.
41. Hunter PR, Nichols G. 2002. Epidemiology and clinical features of Cryptosporidium infection in immunocompromised patients. Clin. Microbiol. Rev. 15:145-154. http://dx.doi.org/10.1128/CMR.15.1.145-154.2002. (Pubitemid 34052587)
42. Rehg J. 1994. New potential therapies for cryptosporidiosis: an analysis of variables affecting drug efficacy. Folia Parasitol. (Praha) 41:23-26.
43. Striepen B, White MW, Li C, Guerini MN, Malik SB, Logsdon JM, Jr, Liu C, Abrahamsen MS. 2002. Genetic complementation in apicomplexan parasites. Proc. Natl. Acad. Sci. U. S. A. 99:6304-6309. http://dx.doi.org/10.1073/pnas. 092525699. (Pubitemid 34493307)
44. Umejiego NN, Gollapalli D, Sharling L, Volftsun A, Lu J, Benjamin NN, Stroupe AH, Riera TV, Striepen B, Hedstrom L. 2008. Targeting a prokaryotic protein in a eukaryotic pathogen: identification of lead compounds against cryptosporidiosis. Chem. Biol. 15:70-77. http://dx.doi.org/10.1016/j.chembiol. 2007.12.010.
45. Maurya SK, Gollapalli DR, Kirubakaran S, Zhang M, Johnson CR, Benjamin NN, Hedstrom L, Cuny GD. 2009. Triazole inhibitors of Cryptosporidium parvum inosine 5=-monophosphate dehydrogenase. J. Med. Chem. 52:4623-4630. http://dx.doi.org/10.1021/jm900410u.
46. MacPherson IS, Kirubakaran S, Gorla SK, Riera TV, D'Aquino JA, Zhang M, Cuny GD, Hedstrom L. 2010. The structural basis of Cryptosporidium-specific IMP dehydrogenase inhibitor selectivity. J. Am. Chem. Soc. 132:1230-1231. http://dx.doi.org/10.1021/ja909947a.
47. Kirubakaran S, Gorla SK, Sharling L, Zhang M, Liu X, Ray SS, Macpherson IS, Striepen B, Hedstrom L, Cuny GD. 2012. Structure-activity relationship study of selective benzimidazole-based inhibitors of Cryptosporidium parvum IMPDH. Bioorg. Med. Chem. Lett. 22:1985-1988. http://dx.doi.org/10.1016/j.bmcl.2012.01. 029.
48. Gorla SK, Kavitha M, Zhang M, Liu X, Sharling L, Gollapalli DR, Striepen B, Hedstrom L, Cuny GD. 2012. Selective and potent urea inhibitors of Cryptosporidium parvum inosine 5=-monophosphate dehydrogenase. J. Med. Chem. 55:7759-7771. http://dx.doi.org/10.1021/jm3007917.
49. Johnson CR, Gorla SK, Kavitha M, Zhang M, Liu X, Striepen B, Mead JR, Cuny GD, Hedstrom L. 2013. Phthalazinone inhibitors of inosine-5′- monophosphate dehydrogenase from Cryptosporidium parvum. Bioorg. Med. Chem. Lett. 23:1004-1007. http://dx.doi.org/10.1016/j.bmcl.2012.12.037.
50. Gorla SK, Kavitha M, Zhang M, Chin JE, Liu X, Striepen B, Makowska-Grzyska M, Kim Y, Joachimiak A, Hedstrom L, Cuny GD. 2013. Optimization of benzoxazole-based inhibitors of Cryptosporidium parvum inosine 5=-monophosphate dehydrogenase. J. Med. Chem. 56:4028-4043. http://dx.doi.org/ 10.1021/jm400241j.
51. Ehigiator HN, Romagnoli P, Borgelt K, Fernandez M, McNair N, Secor WE, Mead JR. 2005. Mucosal cytokine and antigen-specific responses to Cryptosporidium parvum in IL-12p40 KO mice. Parasite Immunol. 27: 17-28. http://dx.doi.org/10.1111/j.1365-3024.2005.00736.x. (Pubitemid 40524989)
52. Mead JR, McNair N. 2006. Antiparasitic activity of flavonoids and isoflavones against Cryptosporidium parvum and Encephalitozoon intestinalis. FEMS Microbiol. Lett. 259:153-157. http://dx.doi.org/10.1111/j.1574-6968.2006. 00263.x.
53. Arrowood MJ, Sterling CR. 1987. Isolation of Cryptosporidium oocysts and sporozoites using discontinuous sucrose and isopycnic Percoll gradients. J. Parasitol. 73:314-319. http://dx.doi.org/10.2307/3282084. (Pubitemid 17121691)
54. Sharling L, Liu X, Gollapalli DR, Maurya SK, Hedstrom L, Striepen B. 2010. A screening pipeline for antiparasitic agents targeting cryptosporidium inosine monophosphate dehydrogenase. PLoS Negl. Trop. Dis. 4:e794. http://dx.doi.org/10.1371/journal.pntd.0000794.
55. Campbell LD, Stewart JN, Mead JR. 2002. Susceptibility to Cryptosporidium parvum infections in cytokine- and chemokine-receptor knockout mice. J. Parasitol. 88:1014-1016. http://dx.doi.org/10.1645/0022-3395(2002)088[1014: STCPII]2.0.CO;2. (Pubitemid 35278754)
56. Arrowood MJ, Donaldson K. 1996. Improved purification methods for calf-derived Cryptosporidium parvum oocysts using discontinuous sucrose and cesium chloride gradients. J. Eukaryot. Microbiol. 43:89S. http://dx.doi.org/10. 1111/j.1550-7408.1996.tb05015.x. (Pubitemid 26352332)
57. Arrowood MJ, Hurd MR, Mead JR. 1995. A new method for evaluating experimental cryptosporidial parasite loads using immunofluorescent flow cytometry. J. Parasitol. 81:404-409. http://dx.doi.org/10.2307/3283822.
58. Yang Z, Wang JR, Niu T, Gao S, Yin T, You M, Jiang ZH, Hu M. 2012. Inhibition of P-glycoprotein leads to improved oral bioavailability of compound K, an anticancer metabolite of red ginseng extract produced by gut microflora. Drug Metab. Dispos. 40:1538-1544. http://dx.doi.org/10.1124/dmd.111.044008.
59. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer N, Pena AG, Goodrich JK, Gordon JI, Huttley GA, Kelley ST, Knights D, Koenig JE, Ley RE, Lozupone CA, McDonald D, Muegge BD, Pirrung M, Reeder J, Sevinsky JR, Turnbaugh PJ, Walters WA, Widmann J, Yatsunenko T, Zaneveld J, Knight R. 2010. QIIME allows analysis of high-throughput community sequencing data. Nat. Methods 7:335-336. http://dx.doi.org/10.1038/nmeth.f.303.
60. Edgar RC. 2010. Search and clustering orders of magnitude faster than BLAST. Bioinformatics 26:2460-2461. http://dx.doi.org/10.1093/bioinformatics/ btq461.
61. DeSantis TZ, Hugenholtz P, Larsen N, Rojas M, Brodie EL, Keller K, Huber T, Dalevi D, Hu P, Andersen GL. 2006. Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. Appl. Environ. Microbiol. 72:5069-5072. http://dx.doi.org/10.1128/AEM.03006-05. (Pubitemid 44078840)
62. Caporaso JG, Bittinger K, Bushman FD, DeSantis TZ, Andersen GL, Knight R. 2010. PyNAST: a flexible tool for aligning sequences to a template alignment. Bioinformatics 26:266-267. http://dx.doi.org/10.1093/bioinformatics/btp636.
63. Price MN, Dehal PS, Arkin AP. 2009. FastTree: computing large minimum evolution trees with profiles instead of a distance matrix. Mol. Biol. Evol. 26:1641-1650. http://dx.doi.org/10.1093/molbev/msp077.
64. Lozupone C, Knight R. 2005. UniFrac: a new phylogenetic method for comparing microbial communities. Appl. Environ. Microbiol. 71:8228-8235. http://dx.doi.org/10.1128/AEM.71.12.8228-8235.2005. (Pubitemid 41803949)
65. Lozupone C, Lladser ME, Knights D, Stombaugh J, Knight R. 2011. UniFrac: an effective distance metric for microbial community comparison. ISME J. 5:169-172. http://dx.doi.org/10.1038/ismej.2010.133.
66. Lozupone C, Hamady M, Knight R. 2006. UniFrac - an online tool for comparing microbial community diversity in a phylogenetic context. BMC Bioinformatics 7:371. http://dx.doi.org/10.1186/1471-2105-7-371.
67. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 2001. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46:3-26. http://dx.doi.org/10.1016/S0169-409X(00)00129-0. (Pubitemid 33653411)
68. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. 2002. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 45:2615-2623. http://dx.doi.org/10.1021/jm020017n. (Pubitemid 34595232)
69. Gargala G, Delaunay A, Li X, Brasseur P, Favennec L, Ballet JJ. 2000. Efficacy of nitazoxanide, tizoxanide and tizoxanide glucuronide against Cryptosporidium parvum development in sporozoite-infected HCT-8 enterocytic cells. J. Antimicrob. Chemother. 46:57-60. http://dx.doi.org/10.1093/jac/46.1. 57. (Pubitemid 30466196)
70. Griffiths JK, Theodos C, Paris M, Tzipori S. 1998. The gamma interferon gene knockout mouse: a highly sensitive model for evaluation of therapeutic agents against Cryptosporidium parvum. J. Clin. Microbiol. 36:2503-2508. (Pubitemid 28380946)
71. Theodos CM, Griffiths JK, D'Onfro J, Fairfield A, Tzipori S. 1998. Efficacy of nitazoxanide against Cryptosporidium parvum in cell culture and in animal models. Antimicrob. Agents Chemother. 42:1959-1965. (Pubitemid 28363076)
72. Hidalgo IJ. 2001. Assessing the absorption of new pharmaceuticals. Curr. Top. Med. Chem. 1:385-401. http://dx.doi.org/10.2174/1568026013395010.
73. Hu M, Borchardt RT. 1992. Transport of a large neutral amino acid in a human intestinal epithelial cell line (Caco-2): uptake and efflux of phenylalanine. Biochim. Biophys. Acta 1135:233-244. http://dx.doi.org/10.1016/ 0167-4889(92)90226-2.
74. Gollapalli DR, Macpherson IS, Liechti G, Gorla SK, Goldberg JB, Hedstrom L. 2010. Structural determinants of inhibitor selectivity in prokaryotic IMP dehydrogenases. Chem. Biol. 17:1084-1091. http://dx.doi.org/10.1016/j.chembiol. 2010.07.014.
75. Griffiths JK, Balakrishnan R, Widmer G, Tzipori S. 1998. Paromomycin and geneticin inhibit intracellular Cryptosporidium parvum without trafficking through the host cell cytoplasm: implications for drug delivery. Infect. Immun. 66:3874-3883. (Pubitemid 28347850)
76. Baishanbo A, Gargala G, Duclos C, Francois A, Rossignol JF, Ballet JJ, Favennec L. 2006. Efficacy of nitazoxanide and paromomycin in biliary tract cryptosporidiosis in an immunosuppressed gerbil model. J. Antimicrob. Chemother. 57:353-355. http://dx.doi.org/10.1093/jac/dki456. (Pubitemid 43160183)
77. Schwarz R, Kaspar A, Seelig J, Kunnecke B. 2002. Gastrointestinal transit times in mice and humans measured with 27Al and 19F nuclear magnetic resonance. Magn. Reson. Med. 48:255-261. http://dx.doi.org/10.1002/mrm.10207. (Pubitemid 34809413)
78. Marona HR, Lucchesi MB. 2004. Protocol to refine intestinal motility test in mice. Lab. Anim. 38:257-260. http://dx.doi.org/10.1258/002367704323133637. (Pubitemid 38962074)
79. Casburn-Jones AC, Farthing MJ. 2004. Management of infectious diarrhoea. Gut 53:296-305. http://dx.doi.org/10.1136/gut.2003.022103. (Pubitemid 38125522)
80. Kelly D, Delday MI, Mulder I. 2012. Microbes and microbial effector molecules in treatment of inflammatory disorders. Immunol. Rev. 245: 27-44. http://dx.doi.org/10.1111/j.1600-065X.2011.01079.x.
81. Kamada N, Seo SU, Chen GY, Nunez G. 2013. Role of the gut microbiota in immunity and inflammatory disease. Nat. Rev. Immunol. 13:321-335. http://dx.doi.org/10.1038/nri3430.
82. Tzipori S, Rand W, Griffiths J, Widmer G, Crabb J. 1994. Evaluation of an animal model system for cryptosporidiosis: therapeutic efficacy of paromomycin and hyperimmune bovine colostrum-immunoglobulin. Clin. Diagn. Lab. Immunol. 1:450-463. (Pubitemid 2111080)
83. Travers MA, Florent I, Kohl L, Grellier P. 2011. Probiotics for the control of parasites: an overview. J. Parasitol. Res. 2011:610769. http://dx.doi.org/10.1155/2011/610769.
84. Pickerd N, Tuthill D. 2004. Resolution of cryptosporidiosis with probiotic treatment. Postgrad. Med. J. 80:112-113. http://dx.doi.org/10.1136/ pmj.2003.014175. (Pubitemid 38297247)
85. Harp JA, Chen W, Harmsen AG. 1992. Resistance of severe combined immunodeficient mice to infection with Cryptosporidium parvum: the importance of intestinal microflora. Infect. Immun. 60:3509-3512.
86. Lantier L, Drouet F, Guesdon W, Mancassola R, Metton C, Lo-Man R, Werts C, Laurent F, Lacroix-Lamandé S. 15 October 2013. Poly(I:C)- induced-protection of neonatal mice against intestinal Cryptosporidium parvum infection requires an additional TLR5 signal provided by the gut flora. J. Infect. Dis. http://dx.doi.org/10.1093/infdis/jit432.
87. Huang J, Mullapudi N, Lancto CA, Scott M, Abrahamsen MS, Kissinger JC. 2004. Phylogenomic evidence supports past endosymbiosis, intracellular and horizontal gene transfer in Cryptosporidium parvum. Genome Biol. 5:R88. http://dx.doi.org/10.1186/gb-2004-5-11-r88.